]>
IRCT20250527065938N1 IRCT 2025-06-20 No. 971941913114، Yakhchal Street، Dr. Shariati Street, Tehran, Iran. Assessment of Tacrolimus Efficacy in Patients with Recurrent Pregnancy Loss. Assessment of Tacrolimus Efficacy in Patients with Recurrent Pregnancy Loss. 2025-06-06 anticipated 100 Complete https://irct.ir/trial/84101 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 3 Recurrent Pregnancy Loss .. Intervention 1: Intervention group .Tacrolimus prescription. Intervention 2: Control group: Follow pregnant women without take Tacrolimus. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information
public Somayyeh Shaikhalian Zafarghandi
No. 6, Unit 10, 4th Floor، Eftekhariyan Street, Azizi AlleyPasdaran, Heravi Square, Mobarak Abad 3-way,Tehran,Iran.
Tehran Iran (Islamic Republic of) 1669743789 +98 912 612 0791 mahyar.fasihi80@gmail.com Avicenna Infertility Center Dr. Shariati Street, Yakhchal Street,Tehran,Iran. scientific Somayyeh Shaikhaluan Zafatghandi
No. 6, Unit 10, 4th Floor, Azizi Alley, Eftekhariyan Street, Heravi Square, Mobarak Abad 3-way, Tehran, Iran.
Tehran Iran (Islamic Republic of) 1669743789 +98 912 612 0791 mahyar.fasihi80@gmail.com Avicenna Infertility Research Center Iran (Islamic Republic of) Women aged between 20 and 39 years. Patients who presented for treatment of recurrent miscarriage (three or more miscarriages before 12 weeks of gestation, with documented fetal heart rate [FHR]). Patients with unexplained infertility despite evaluation, including assessment of ovulatory function, tubal patency, uterine anatomical abnormalities, cervical factors, and sperm quality and quantity. Patients who are able to continue regular follow-up visits during the study period. 20 years 39 years Female Patients using immunosuppressive medications for infertility treatment, such as azathioprine, mizoribine, mycophenolate mofetil, cyclophosphamide, sirolimus, everolimus, cyclosporine, basiliximab, etanercept, golimumab, cantuzumab, tocilizumab, conatumumab, corticosteroids, or intravenous immunoglobulin (IVIG). Chronic endometritis diagnosed by endometrial biopsy. Uterine anomalies, uterine fibroids, endometrial polyps, or intrauterine adhesions. Active infections including HIV, hepatitis B, hepatitis C, or other active viral diseases. Tacrolimus Tacrolimus Efficacy in Patients with Recurrent Pregnancy Loss . Treatment - Drugs Treatment - Drugs Intervention group .Tacrolimus prescription Control group: Follow pregnant women without take Tacrolimus. Live Births . Timepoint: Evaluation of the Effect of Tacrolimus on Recurrent Pregnancy Loss Based on the Number of Live Births 18 month evaluation. Method of measurement: Evaluation of the Effect of Tacrolimus on Recurrent Pregnancy Loss Based on the Number of Live Births. No. 971941913114، Yakhchal Street، Dr. Shariati Street, Tehran, Iran. Approved 2025-05-25 Avicenna Research Institute, Iranian Academic Center for Education, Culture and Research (ACECR) Shahid Beheshti University, Rashideddin Fazlollah Street, Yemen Street, Chamran Expressway (North to South), Tehran, Iran. Tehran Tehran Iran (Islamic Republic of)